ENVESOME Particokinetics

This record contains the Particokinetics-specific modelling outputs reported in ENVESOME Deliverable D6.1, “Report on reverse QIVIVE and BCF for chemicals based on the external exposome”, produced within ENVESOME — The Environmental Exposome and Health (Horizon Europe Grant Agreement No. 101157269).

The deposited material is restricted to the ENVESOME-Particokinetics workflow. D6.1 describes this as a forward compartmental model for estimating human internal particle-dose descriptors following inhalation exposure. The model links respiratory deposition, lung retention, mucociliary and gastrointestinal clearance, lymphatic drainage, blood circulation, systemic tissue distribution and mass-balance accounting. Reverse dosimetry was not applied to particles.

The archive contains the Particokinetics structural model figure, dust and pollen exposure-scenario outputs, literature-derived black carbon and ultrafine-particle scenarios, concentration-data-source information, lower-respiratory deposition results, model QA and uncertainty summaries, and the final WP7 dose-regime table for PM10 dust, six pollen taxa, black carbon and ultrafine particles.

D6.1 reports 101 forward-dosimetry scenarios: 91 dust/pollen scenarios and 10 black carbon/UFP scenarios. Black carbon and UFP inputs are literature-derived European screening scenarios rather than project-measured inputs. Lung-deposition evaluation reproduced the expected size-dependent behaviour, with coarse PM10 dust and pollen dominated by extrathoracic/proximal deposition and black carbon/UFP showing a higher relative distal/alveolar contribution. Approximate alveolar fractions of 0.198–0.199 are reported for black carbon and UFP.

All deposition matrices passed the required ET + G1–G24 / 25×N structural checks, with a validated 25-row deposition matrix for each particle category. All central and uncertainty-member simulations completed with QA-pass status, and mass-balance/high-dose checks confirmed that deposited mass did not exceed inhaled mass where both were available.

Uncertainty was represented using a deterministic screening design with five percentile-like members (P05, P25, P50, P75 and P95). These values are screening intervals rather than validated statistical confidence intervals.

The WP7 output covers nine particle categories — PM10 dust, alder pollen, birch pollen, grass pollen, mugwort pollen, olive pollen, ragweed pollen, black carbon and UFP — across five target domains. The reported dose regimes comprise 45 task–tissue rows and 270 primary dose anchors, with six model-informed experimental concentrations per row evaluated at 0, 6, 24, 48, 72 and 96 h.

The strongest evidential support applies to respiratory deposition and lung-linked descriptors. Systemic-organ and brain-route outputs should be interpreted more cautiously because direct human particle tissue-kinetic data remain limited. These outputs are internal-dose anchors and should not be interpreted as HBM-based reverse-dosimetry outputs, reverse-QIVIVE estimates or ready-to-use culture-medium doses.

All figures and numerical values contained in this archive are extracted or transcribed from the supplied final D6.1 deliverable. No new particle simulations or external datasets were introduced in preparing this deposit.